PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Coles, Alasdair J.
TI  - CARE-MS I Follow-up: Alemtuzumab Efficacy, Safety for MS Treatment Maintained for More than 4 Years
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 11--12
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/11.short
4100  - http://mdc.sagepub.com/content/14/29/11.full
AB  - An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [NCT00930553; Coles AJ et al. ECTRIMS 2014 (poster P090)], a follow-up to the phase 3, randomized, head-to-head CARE-MS I study [NCT00530348], has demonstrated the continuing efficacy and safety of subcutaneous alemtuzumab in treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) who were treated for up to 4 years.